home / stock / onct / onct news

ONCT News and Press, Oncternal Therapeutics Inc. From 11/09/23

Stock Information
Company Name: Oncternal Therapeutics Inc.
Stock Symbol: ONCT
Market: NYSE
Website: oncternal.com
Menu
ONCT ONCT Quote ONCT Short ONCT News ONCT Articles ONCT Message Board
Get ONCT Alerts

News, Short Squeeze, Breakout and More Instantly...
ONCT - Expected US Company Earnings on Thursday, November 9th, 2023

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
ONCT - Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2023 financial results after the U.S. financial markets cl...

ONCT - Expected US Company Earnings on Thursday, November 2nd, 2023

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

ONCT - Expected earnings - Oncternal Therapeutics Inc.

Oncternal Therapeutics Inc. (ONCT) is expected to report $-0.15 for Q3 2023
ONCT - Oncternal stock jumps 9% on FDA fast track designation

2023-10-26 10:50:13 ET More on Oncternal Therapeutics Oncternal Therapeutics, Inc. (ONCT) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Oncternal Therapeutics Historical earnings data for Oncternal Therapeutics Financial information ...

ONCT - Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-act...

ONCT - Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board ...
ONCT - Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study ...

ONCT - Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board

SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Prostate Cancer Scientific Advisory Board (SAB). The Prostate Canc...

ONCT - Oncternal Therapeutics, Inc. (ONCT) Q2 2023 Earnings Call Transcript

2023-08-10 20:43:04 ET Oncternal Therapeutics, Inc. (ONCT) Q2 2023 Earnings Conference Call August 10, 2023 05:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Conference Call Participants Carl By...
Previous 10 Next 10